Mode
Text Size
Log in / Sign up

PETRA-MRA shows improved image quality and occlusion rates in intracranial aneurysm follow-up

PETRA-MRA shows improved image quality and occlusion rates in intracranial aneurysm follow-up
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider PETRA-MRA for noninvasive aneurysm surveillance, but evidence is preliminary.

This prospective comparative study evaluated 100 patients with 100 intracranial aneurysms, comparing PETRA-MRA to TOF-MRA, DSA, and outcomes after stent-assisted coiling (SAC) versus flow diverter (FD) placement. The primary outcomes were parent artery image quality and aneurysm occlusion status, assessed at postoperative day 1 (T0) and 6 months (T1). PETRA-MRA image quality significantly improved at T1 compared to T0, with higher scores in the FD group than the SAC group at T1. No pre-specified covariates showed statistically significant independent associations with image quality at T1. Complete occlusion rates increased from T0 to T1: in the FD group, from 21.4% to 71.4%, and in the SAC group, from 80.6% to 91.7%. PETRA-MRA demonstrated higher diagnostic accuracy than TOF-MRA in the SAC group, with accuracies of 94.44% at T0 and 97.67% at T1. Safety and tolerability data were not reported. Key limitations include the lack of reported effect sizes, p-values, or confidence intervals for most outcomes, and the absence of safety information. The study suggests PETRA-MRA has potential as a noninvasive alternative to DSA for long-term surveillance after intracranial aneurysm treatment, but its clinical utility requires confirmation in larger, more rigorous studies.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveMetal-related susceptibility artifacts have long limited the use of magnetic resonance angiography (MRA) for postoperative surveillance after intracranial aneurysm interventions. Pointwise encoding time reduction with radial acquisition (PETRA) substantially reduces metal-induced artifacts. This study aimed to evaluate the performance of PETRA-MRA in depicting parent artery image quality and aneurysm occlusion status at postoperative day 1 (T0) and 6 months (T1), and to explore its feasibility as a noninvasive alternative to digital subtraction angiography (DSA) for follow-up.MethodsIn this prospective study, 100 patients harboring 100 intracranial aneurysms underwent time-of-flight MRA (TOF-MRA), PETRA-MRA, and DSA at both T0 and T1. Parent artery image quality was compared across time points and treatment modalities stent-assisted coiling (SAC) vs. flow diverter (FD) placement alone. A parsimonious cumulative logit regression model was performed to identify factors associated with PETRA-MRA image quality. Using DSA as the reference standard, the sensitivity, specificity, and accuracy of PETRA-MRA for assessing aneurysm occlusion were calculated.ResultsAcross both treatment groups, PETRA-MRA demonstrated significantly improved image quality at T1 compared with T0. At T1, both TOF-MRA and PETRA-MRA yielded higher image quality scores in the FD group than in the SAC group. Regression analysis indicated that none of the pre-specified covariates demonstrated a statistically significant independent association with PETRA-MRA image quality at T1 based on bootstrap-based inference. Complete occlusion rates increased markedly from T0 to T1: from 21.4% to 71.4% in the FD group and from 80.6% to 91.7% in the SAC group. Using DSA as the reference standard, PETRA-MRA demonstrated higher diagnostic accuracy than TOF-MRA at both time points in the SAC group, with accuracies of 94.44% in T0 and 97.67% in T1.ConclusionPETRA-MRA demonstrates improved diagnostic performance at mid-term follow-up compared with the early postoperative period. Its marked ability to reduce metal artifacts and enhance visualization of both the parent artery and aneurysm lumen supports its potential as an effective, noninvasive alternative to DSA for long-term surveillance after intracranial aneurysm treatment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.